Ampio plans biotech spinoff; Stem Cell Therapeutics raises $33M;

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Why is it a CEO can't be fired or quit? Amarin's Joe Z "retires." joins a long list of biotech retirees who either jumped or were pushed. More | Follow @JohnCFierce

@DamianFierce: Genentech wrote a solid guide to some of the methodology used in the much-discussed I-SPY 2 studies. More from Genetech | Follow @DamianFierce

@EmilyMFierce: Booster of red blood cells synthesized for first time. Story via SciAm | Follow @EmilyMFierce

> Ampio Pharmaceuticals ($AMPE) is spinning off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals, which will turn to an IPO to raise funds. Release

> Toronto-based Stem Cell Therapeutics has raised $33 million to back development of its lead cancer stem cell therapy through Phase I. Special Situations Funds, Ridgeback Capital, Merlin Nexus, Sabby Capital, venBio, Opaleye Management and HSMR Advisors committed cash. Release

> AmpliPhi BioSciences, which has a partnership deal with Intrexon ($XON), has raised $18 million to support its work on bacteriophage-based antibacterial therapies to treat drug-resistant infections. Release

> Retrophin ($RTRX) has pulled the plug on its $4-per-share offer for struggling Transcept Pharmaceuticals ($TSPT), a biotech that has said it will liquidate if it can't find a buyer in the next few months. Release

Medical Device News

@FierceMedDev: Mindray climbs back from damage done on Twitter. Article | Follow @FierceMedDev

@MarkHFierce: Solta Medical, an aesthetic med device maker with sagging sales, will sell itself for $250M. Reorganization wasn't enough. Story | Follow @MarkHFierce

@MichaelGFierce: To deliver drugs, German engineers took a cue from some of the best swimmers in nature: sperm cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Here's what 21 tweets can do to your reputation: Mindray climbs back from damage done on Twitter. More | Follow @GalenMoore

> GE Healthcare plans 100 new products to address massive India growth. More

> Siemens becomes one of Pfizer's many companion diagnostics suitors. News

> FDA approves eNeura's brain-stimulation device to treat migraines. Report

Pharma News

@FiercePharma:  Endo to Acquire Specialty Pharmaceutical Company NuPathe. Release | Follow @FiercePharma

@EricPFierce: Bloomberg says drugmakers make catch a break on in Germany, price cuts and rebates may fall next year. More | Follow @EricPFierce

@CarlyHFierce: Sanofi signs on to sell Vivus ED drug in emerging markets. Friday's story | Follow @CarlyHFierce

> China rounds up counterfeiters as the FDA boosts its oversight there. More

> GlaxoSmithKline bets another $1B on India with stake-raising buyout offer. News

> More new drugs, yes. Lots more sales? Not always, thanks to skeptical payers. Story

CRO News

> Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug. Story

> Quotient Clinical is the latest CRO snapped up by private equity. Report

> Belgian CRO Genae reaches into Switzerland for medical device work. News

> Bayer teams up with Texas' MD Anderson for cancer clinical trials. More

> Charles River shakes up its leadership to cut costs and boost sales. Article

> CROS NT names a new CEO amid its global push. Item

Biotech IT News

>  Twitter-driven stock furor prompts exchange to fine Medivir. More

> Court fines Boehringer $1M for 'gross inadequacy' of record keeping. News

> Merck turns to gamification to help Type 2 diabetics. Article

> Accelrys inks $50M Qumas takeover to continue deal-driven expansion. Report

> BGI is building a huge genome database to drive drug discovery. Story

> NIH names its first associate director of data science. Item

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.